IPO Journey
Hemab Therapeutics Holdings, Inc.
IPO Date: May 1, 2026 · 5 filings tracked
Final Offer Terms
Ticker
COAG
Exchange
Nasdaq Global Select Market
Offer Price
$18.00
Shares Offered
16,750,000
Estimated Proceeds
$301.5M
Expected Listing
May 04, 2026
Underwriters
Led by Goldman Sachs & Co. LLC, Jefferies
Evercore ISIWedbush PacGrow
Filing Timeline
1
S-1
April 10, 2026
- Developing innovative antibody-based therapies for rare blood-clotting disorders.
- Lead drug candidate sutacimig (HMB-001) targeting Phase 3 clinical trials.
2
S-1/A
April 27, 2026
- Clinical-stage focus on high-unmet-need rare blood-clotting disorders
- Lead candidate sutacimig (HMB-001) targeting multiple indications
Changes from previous filing
- ▸ Expected offer range: $16.0 – $18.0 per share
- ▸ Shares offered: 11,764,706
- ▸ Estimated proceeds: $188M
3
S-1/A
April 28, 2026
- Developing preventative treatments for rare bleeding and clotting disorders
- Lead drug candidate HMB-001 currently in early-stage human trials
Changes from previous filing
- ▸ Ticker symbol removed
- ▸ Price range removed
4
S-1/A
April 30, 2026
- Specialized focus on preventative treatments for rare bleeding disorders
- Lead drug candidate 'sutacimig' currently in early-to-mid-stage clinical trials
Changes from previous filing
- ▸ Ticker symbol: COAG
- ▸ Expected offer range: $16.0 – $18.0 per share
- ▸ Shares offered: 15,000,000
- ▸ Estimated proceeds: $240M
- ▸ Underwriters: Goldman Sachs & Co. LLC, Jefferies, Evercore ISI, Wedbush PacGrow
424B4
Final Pricing
May 1, 2026
- Focus on high-unmet-need rare blood-clotting disorders
- Advanced pipeline featuring Sutacimig (HMB-001) in clinical trials
Changes from previous filing
- ▸ Price range removed
- ▸ Final offer price: $18.0 per share
- ▸ Shares offered: 16,750,000
- ▸ Estimated proceeds: $301M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.